William Delaney

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kato D, Choy RW, Canales E, Dick RA, Lake AD, Shapiro ND, Chin E, Li J, Zhang JR, Wu Q, Saito RD, Metobo S, Aktoudianakis E, Schroeder SD, Yang ZY, Glatt DM, Balsitis S, Gamelin L, Yu M, Cheng G, Delaney WE, Link JO. Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873. ACS Med Chem Lett. 2024 Apr 11; 15(4):546-554. PMID: 38628802.
      Citations:    
    2. Burdette D, Hyrina A, Song Z, Beran RK, Cheung T, Gilmore S, Kobayashi T, Li L, Liu Y, Niedziela-Majka A, Medley J, Mehra U, Morganelli P, Novikov N, Niu C, Tam D, Tang J, Wang J, Yue Q, Fletcher SP, Holdorf MM, Delaney WE, Feierbach B, Lazerwith S. Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0134822. PMID: 36519892.
      Citations:    
    3. Gilmore SA, Tam D, Cheung TL, Snyder C, Farand J, Dick R, Matles M, Feng JY, Ramirez R, Li L, Yu H, Xu Y, Barnes D, Czerwieniec G, Brendza KM, Appleby TC, Birkus G, Willkom M, Kobayashi T, Paoli E, Labelle M, Boesen T, Tay CH, Delaney WE, Notte GT, Schmitz U, Feierbach B. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus. PLoS One. 2022; 17(12):e0271145. PMID: 36477212.
      Citations:    
    4. Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, Miller V, Janssen HLA. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol. 2022 12; 19(12):748-750. PMID: 36207612.
      Citations:    
    5. Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van B?mmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol. 2022 11; 19(11):727-745. PMID: 35859026.
      Citations:    
    6. Ramirez R, van Buuren N, Gamelin L, Soulette C, May L, Han D, Yu M, Choy R, Cheng G, Bhardwaj N, Chiu J, Muench RC, Delaney WE, Mo H, Feierbach B, Li L. Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines. J Virol. 2021 09 09; 95(19):e0029921. PMID: 34287049.
      Citations:    
    7. Hong X, Luckenbaugh L, Mendenhall M, Walsh R, Cabuang L, Soppe S, Revill PA, Burdette D, Feierbach B, Delaney W, Hu J. Characterization of Hepatitis B Precore/Core-Related Antigens. J Virol. 2021 01 13; 95(3). PMID: 33148795.
      Citations:    
    8. Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, Ramakrishnan D, Pattabiraman D, Spurlock S, Chu R, Kang D, Mish M, Ramirez R, Li L, Li B, Ma S, Hung M, Voitenleitner C, Yon C, Suresh M, Menne S, Cote P, Delaney WE, Mackman R, Fletcher SP. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B. Hepatology. 2021 01; 73(1):53-67. PMID: 32246499.
      Citations:    
    9. Fumagalli V, Di Lucia P, Venzin V, Bono EB, Jordan R, Frey CR, Delaney W, Chisari FV, Guidotti LG, Iannacone M. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med. 2020 11 02; 217(11). PMID: 32761167.
      Citations:    
    10. Mackman RL, Mish M, Chin G, Perry JK, Appleby T, Aktoudianakis V, Metobo S, Pyun P, Niu C, Daffis S, Yu H, Zheng J, Villasenor AG, Zablocki J, Chamberlain J, Jin H, Lee G, Suekawa-Pirrone K, Santos R, Delaney WE, Fletcher SP. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 09 24; 63(18):10188-10203. PMID: 32407112.
      Citations:    
    11. Chen CY, Winer BY, Chavez D, Guerra B, Brasky KM, Eng S, Salas E, Tam D, Simmons JH, Abee CR, Delaney WE, Ploss A, Lanford RE, Voitenleitner C. Woolly Monkey-HBV Infection in Squirrel Monkeys as a Surrogate Nonhuman Primate Model of HBV Infection. Hepatol Commun. 2020 Mar; 4(3):371-386. PMID: 32140655.
      Citations:    
    12. Li L, Barry V, Daffis S, Niu C, Huntzicker E, French DM, Mikaelian I, Lanford RE, Delaney WE, Fletcher SP. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells. J Hepatol. 2018 05; 68(5):912-921. PMID: 29247724.
      Citations:    
    13. Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, Salas E, Chu R, Ramos H, Livingston CM, Beran RK, Garg AV, Balsitis S, Durantel D, Zoulim F, Delaney WE, Fletcher SP. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. J Hepatol. 2018 05; 68(5):922-931. PMID: 29247725.
      Citations:    
    14. Liu Y, Cathcart AL, Delaney WE, Kitrinos KM. Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment. J Virol Methods. 2017 11; 249:189-193. PMID: 28923315.
      Citations:    
    15. Ning X, Basagoudanavar SH, Liu K, Luckenbaugh L, Wei D, Wang C, Wei B, Zhao Y, Yan T, Delaney W, Hu J. Capsid Phosphorylation State and Hepadnavirus Virion Secretion. J Virol. 2017 05 01; 91(9). PMID: 28228589.
      Citations:    
    16. Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157. PMID: 28132867.
      Citations:    
    17. Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420. PMID: 28106531.
      Citations:    
    18. Niu C, Livingston CM, Li L, Beran RK, Daffis S, Ramakrishnan D, Burdette D, Peiser L, Salas E, Ramos H, Yu M, Cheng G, Strubin M, Delaney WE, Fletcher SP. The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS One. 2017; 12(1):e0169648. PMID: 28095508.
      Citations:    
    19. Ludgate L, Liu K, Luckenbaugh L, Streck N, Eng S, Voitenleitner C, Delaney WE, Hu J. Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation. J Virol. 2016 06 15; 90(12):5830-5844. PMID: 27076641.
      Citations:    
    20. Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Antimicrob Agents Chemother. 2016 Jan 11; 60(3):1847-1853. PMID: 26824950.
      Citations:    
    21. Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014 Nov; 58(11):6599-606. PMID: 25155588.
      Citations:    
    22. Barauskas O, Corsa AC, Wang R, Hluhanich S, Jin D, Hung M, Yang H, Delaney WE, Schultz BE. Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir. Biochim Biophys Acta. 2014 Dec; 1840(12):3292-8. PMID: 25139683.
      Citations:    
    23. King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014; 9(7):e101904. PMID: 25051027.
      Citations:    
    24. Phillips B, Cai R, Delaney W, Du Z, Ji M, Jin H, Lee J, Li J, Niedziela-Majka A, Mish M, Pyun HJ, Saugier J, Tirunagari N, Wang J, Yang H, Wu Q, Sheng C, Zonte C. Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J Med Chem. 2014 Mar 13; 57(5):2161-6. PMID: 24512292.
      Citations:    
    25. Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W, Cheng G. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother. 2014 May; 58(5):2638-46. PMID: 24550344.
      Citations:    
    26. Bush CO, Pokrovskii MV, Saito R, Morganelli P, Canales E, Clarke MO, Lazerwith SE, Golde J, Reid BG, Babaoglu K, Pagratis N, Zhong W, Delaney WE, Paulson MS, Beran RK. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother. 2014; 58(1):386-96. PMID: 24165192.
      Citations:    
    27. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, Cheng G. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res. 2013 Nov; 100(2):439-45. PMID: 24013001.
      Citations:    
    28. Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014; 58(2):647-53. PMID: 23939899.
      Citations:    
    29. Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013 Sep; 57(9):4181-9. PMID: 23774432.
      Citations:    
    30. Fletcher SP, Delaney WE. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis. 2013 May; 33(2):130-7. PMID: 23749669.
      Citations:    
    31. Bush CO, Greenstein AE, Delaney WE, Beran RK. Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. PLoS One. 2013; 8(6):e65273. PMID: 23755208.
      Citations:    
    32. Delaney WE. Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome. Antiviral Res. 2013 Jul; 99(1):34-48. PMID: 23602852.
      Citations:    
    33. Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Antivir Ther. 2013; 18(3):311-9. PMID: 23047118.
      Citations:    
    34. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, Cheng G. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology. 2013 Jan; 144(1):59-61.e6. PMID: 23000598.
      Citations:    
    35. Beran RK, Sharma R, Corsa AC, Tian Y, Golde J, Lundgaard G, Delaney WE, Zhong W, Greenstein AE. Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus. PLoS One. 2012; 7(2):e30286. PMID: 22347373.
      Citations:    
    36. Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, Xu J, Kim CU. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett. 2012 Apr 01; 22(7):2629-34. PMID: 22366653.
      Citations:    
    37. Sheng XC, Casarez A, Cai R, Clarke MO, Chen X, Cho A, Delaney WE, Doerffler E, Ji M, Mertzman M, Pakdaman R, Pyun HJ, Rowe T, Wu Q, Xu J, Kim CU. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett. 2012 Feb 01; 22(3):1394-6. PMID: 22244938.
      Citations:    
    38. Chan K, Cheng G, Beran RK, Yang H, Appleby TC, Pokrovskii MV, Mo H, Zhong W, Delaney WE. An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture. Virology. 2012 Jan 20; 422(2):224-34. PMID: 22099378.
      Citations:    
    39. Schultz B, Yang H, Delaney WE. Biochemical evaluation of HCV NS3 protease inhibitors. Curr Protoc Pharmacol. 2011 Sep; Chapter 13:Unit13B.7. PMID: 21898332.
      Citations:    
    40. Robinson M, Tian Y, Pagratis N, Delaney WE. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines. Curr Protoc Microbiol. 2011 Aug; Chapter 17:Unit17.7. PMID: 21805689.
      Citations:    
    41. Robinson M, Tian Y, Delaney WE, Greenstein AE. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc Natl Acad Sci U S A. 2011 Jun 21; 108(25):10290-5. PMID: 21646519.
      Citations:    
    42. Clarke MO, Chen X, Cho A, Delaney WE, Doerffler E, Fardis M, Ji M, Mertzman M, Pakdaman R, Pyun HJ, Rowe T, Yang CY, Sheng XC, Kim CU. Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease. Bioorg Med Chem Lett. 2011 Jun 15; 21(12):3568-72. PMID: 21601450.
      Citations:    
    43. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother. 2011 May; 55(5):2197-205. PMID: 21357305.
      Citations:    
    44. Pokrovskii MV, Bush CO, Beran RK, Robinson MF, Cheng G, Tirunagari N, Fenaux M, Greenstein AE, Zhong W, Delaney WE, Paulson MS. Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics. J Virol. 2011 Apr; 85(8):3978-85. PMID: 21289124.
      Citations:    
    45. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother. 2010 Aug; 54(8):3099-106. PMID: 20516274.
      Citations:    
    46. Sheng XC, Pyun HJ, Chaudhary K, Wang J, Doerffler E, Fleury M, McMurtrie D, Chen X, Delaney WE, Kim CU. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem Lett. 2009 Jul 01; 19(13):3453-7. PMID: 19477126.
      Citations:    
    47. Paulson MS, Yang H, Shih IH, Feng JY, Mabery EM, Robinson MF, Zhong W, Delaney WE. Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. Antiviral Res. 2009 Aug; 83(2):135-42. PMID: 19457562.
      Citations:    
    48. Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 2009 Feb; 81(2):166-73. PMID: 19063924.
      Citations:    
    49. Delaney WE, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol. 2008 Oct; 8(5):532-40. PMID: 18835366.
      Citations:    
    50. Zhu Y, Curtis M, Snow-Lampart A, Yang H, Delaney W, Miller MD, Borroto-Esoda K. In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations. J Clin Microbiol. 2007 Oct; 45(10):3335-41. PMID: 17687019.
      Citations:    
    51. Delaney WE. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother. 2007 May; 59(5):827-32. PMID: 17332007.
      Citations:    
    52. Heipertz RA, Miller TG, Kelley CM, Delaney WE, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol. 2007 Apr; 81(7):3068-76. PMID: 17215289.
      Citations:    
    53. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007; 12(3):355-62. PMID: 17591025.
      Citations:    
    54. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006 Jul; 50(7):2471-7. PMID: 16801428.
      Citations:    
    55. Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE, Xiong S, Gerin JL, Tennant BC. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul; 49(7):2720-8. PMID: 15980342.
      Citations:    
    56. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005; 10(5):625-33. PMID: 16152756.
      Citations:    
    57. Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004 Oct; 48(10):3702-10. PMID: 15388423.
      Citations:    
    58. Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WE, Gerin JL, Tennant BC. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. 2004 Aug; 63(2):115-21. PMID: 15302140.
      Citations:    
    59. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004 Jun; 126(7):1750-8. PMID: 15188170.
      Citations:    
    60. Yang H, Westland C, Xiong S, Delaney WE. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res. 2004 Jan; 61(1):27-36. PMID: 14670591.
      Citations:    
    61. K?ck J, Baumert TF, Delaney WE, Blum HE, von Weizs?cker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology. 2003 Dec; 38(6):1410-8. PMID: 14647052.
      Citations:    
    62. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003 Nov; 77(21):11833-41. PMID: 14557667.
      Citations:    
    63. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003 Aug; 125(2):292-7. PMID: 12891527.
      Citations:    
    64. Westland CE, Yang H, Delaney WE, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL, Xiong S. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003 Jul; 38(1):96-103. PMID: 12829991.
      Citations:    
    65. Westland C, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003 Jul; 125(1):107-16. PMID: 12851876.
      Citations:    
    66. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, Desmond P, Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 2003 Jan; 37(1):27-35. PMID: 12500185.
      Citations:    
    67. Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002 Sep; 46(9):3057-60. PMID: 12183271.
      Citations:    
    68. Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002 Aug; 36(2):464-73. PMID: 12143057.
      Citations:    
    69. Delaney W, Bartholomeusz A, Locarnini SA. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs. 2002 Feb; 11(2):169-87. PMID: 11829711.
      Citations:    
    Delaney's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (250)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _